Literature DB >> 20640454

Early recovery in hemodynamics after direct hemoperfusion with polymyxin B-immobilized fibers may predict mortality rate in patients with septic shock.

Atsuko Kobayashi1, Yasushi Iwasaki, Yuichi Kimura, Yoshiaki Kawagoe, Yoshihito Ujike.   

Abstract

PURPOSE: This retrospective and observational study attempted to determine whether the rapid improvement in hemodynamic parameters and the subsequent discontinuation or decrease of catecholamine infusion shortly after direct hemoperfusion with polymyxin B-immobilized fibers (PMX) may be strong predictors of mortality in patients with septic shock.
METHODS: Retrospectively, 46 patients were divided into two groups; those who survived more than 30 days after PMX (survival group, S group) and those who died within 30 days (nonsurvival group, NS group). Sequential Organ Failure Assessment (SOFA) scores, mean arterial pressure, catecholamine index (CAI), and vasopressor dependency index (VDI) were examined before and after PMX. The same parameters were examined on days 3, 4, 5, 6, 8, and 16 after PMX.
RESULTS: CAI in the S group significantly decreased from 14.7 (95% CI, 10.3-19.1) at baseline to 6.4 (95% CI, 3.7-9.2; P < 0.001) at post-PMX, whereas a significant decrease in CAI was not observed in the NS group (23.1; 95% CI, 15.4-30.7 to 18.1; 95% CI, 11.6-24.7; P = 0.114). The significant decrease in VDI at post-PMX was observed both in the S group and in the NS group. If the cutoff point of VDI at post-PMX is 0.2, there is a significant difference in numbers of the S group (VDI ≥ 0.2, n = 24; VDI < 0.2, n = 2) and NS group (VDI ≥ 0.2, n = 8; VDI < 0.2, n = 20) using Fisher's exact test.
CONCLUSIONS: We concluded that the early improvement in CAI and VDI shortly after PMX might be prognostic indicators for survival.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20640454     DOI: 10.1007/s00540-010-0986-2

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  15 in total

1.  Removal of cytokine inducing substances by polymyxin-B immobilized polystyrene-derivative fibers during in vitro hemoperfusion of 10% human plasma containing Staphylococcus aureus challenge.

Authors:  B L Jaber; T W Barrett; M Cendoroglo Neto; S Sundaram; A J King; B J Pereira
Journal:  ASAIO J       Date:  1998 Jan-Feb       Impact factor: 2.872

2.  Polymyxin B binds to anandamide and inhibits its cytotoxic effect.

Authors:  Y Wang; Y Liu; K P Sarker; M Nakashima; T Serizawa; A Kishida; M Akashi; M Nakata; I Kitajima; I Maruyama
Journal:  FEBS Lett       Date:  2000-03-24       Impact factor: 4.124

3.  A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock.

Authors:  R C Bone; C J Fisher; T P Clemmer; G J Slotman; C A Metz; R A Balk
Journal:  N Engl J Med       Date:  1987-09-10       Impact factor: 91.245

4.  A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection.

Authors:  Jean-Louis Vincent; Pierre-François Laterre; Jonathan Cohen; Hilmar Burchardi; Hajo Bruining; Francisco Alvarez Lerma; Xavier Wittebole; Daniel De Backer; Stephen Brett; Dolores Marzo; Haruji Nakamura; Stephanie John
Journal:  Shock       Date:  2005-05       Impact factor: 3.454

5.  Serial evaluation of the SOFA score to predict outcome in critically ill patients.

Authors:  F L Ferreira; D P Bota; A Bross; C Mélot; J L Vincent
Journal:  JAMA       Date:  2001-10-10       Impact factor: 56.272

6.  The severity of hyperdynamic circulation may predict the effects of direct hemoperfusion with the adsorbent column using polymyxin B-immobilized fiber in patients with gram-negative septic shock.

Authors:  K Uriu; A Osajima; M Kamochi; H Watanabe; K Aibara; K Kaizu
Journal:  Ther Apher       Date:  2001-02

7.  Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine.

Authors:  J L Vincent; A de Mendonça; F Cantraine; R Moreno; J Takala; P M Suter; C L Sprung; F Colardyn; S Blecher
Journal:  Crit Care Med       Date:  1998-11       Impact factor: 7.598

8.  Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial.

Authors:  Dinna N Cruz; Massimo Antonelli; Roberto Fumagalli; Francesca Foltran; Nicola Brienza; Abele Donati; Vincenzo Malcangi; Flavia Petrini; Giada Volta; Franco M Bobbio Pallavicini; Federica Rottoli; Francesco Giunta; Claudio Ronco
Journal:  JAMA       Date:  2009-06-17       Impact factor: 56.272

9.  Hemoperfusion with polymyxin B-immobilized fibers reduced the number of CD16+ CD14+ monocytes in patients with septic shock.

Authors:  Hironori Tsujimoto; Satoshi Ono; Shuichi Hiraki; Takashi Majima; Nobuaki Kawarabayashi; Hidekazu Sugasawa; Manabu Kinoshita; Hoshio Hiraide; Hidetaka Mochizuki
Journal:  J Endotoxin Res       Date:  2004

10.  Early hemodynamic course of septic shock.

Authors:  L Metrangolo; M Fiorillo; G Friedman; P G Silance; R J Kahn; G P Novelli; J L Vincent
Journal:  Crit Care Med       Date:  1995-12       Impact factor: 7.598

View more
  2 in total

1.  Initial central venous pressure could be a prognostic marker for hemodynamic improvement of polymyxin B direct hemoperfusion: a retrospective cohort study.

Authors:  Hiroyuki Yamada; Tatsuo Tsukamoto; Hiromichi Narumiya; Kazumasa Oda; Satoshi Higaki; Ryoji Iizuka; Motoko Yanagita; Masako Deguchi
Journal:  J Intensive Care       Date:  2016-10-10

2.  Prognostic factors in patients with septic shock in digestive surgery who have undergone direct hemoperfusion with polymyxin B-immobilized fibers: a retrospective observational study.

Authors:  Satoshi Matsukuma; Kazuhiko Sakamoto; Mitsuo Nishiyama; Takao Tamesa; Shigefumi Yoshino; Shoichi Hazama; Rumi Oshibuchi; Norimasa Matsuda; Satoshi Matsumoto; Hiroya Wakamatsu; Ryosuke Tsuruta; Mishiya Matsumoto; Masaaki Oka
Journal:  J Intensive Care       Date:  2015-03-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.